AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03376074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cold storage
Description: 75 patients transplanted in Rennes between 2010 and 2015 with a cold stored grafts, matched (ratio 1: 3) using a propensity score calculated according to some parameters
Study NCT03187054 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior or posterior colporrhaphy
Description: will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
Study NCT03187054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior or posterior colporrhaphy
Description: will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
Study NCT01675869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive Training of Attention and Metacognition (ETAM)
Description: ETAM is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).
Study NCT01675869 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Attention Control is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
Study NCT02436395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A (povidone-iodine wash the surgical incision)
Description: Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with povidone-iodine wash the surgical incision
Study NCT02436395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B (normal saline wash the surgical incision)
Description: Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with normal saline wash the surgical incision
Study NCT03057288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiducial markers placement
Description: The main objective of this study is to evaluate the feasibility of fiducial markers placement under EUS guidance for patients with esophageal or rectal cancer with an indication of radiotherapy
Study NCT02914366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol
Study NCT02914366 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03028883 — intervention group
Intervention type: OTHER
Intervention: Dose adjustments
Description: Do higher doses of buprenorphine result in a higher rate of neonatal abstinence syndrome as compared to lower doses of buprenorphine
Study NCT01783483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SternaLock Blue closure system
Description: SternaLock Blue closure system is a primary closure system plate-based
Study NCT01783483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture Wire
Description: Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
Study NCT01701778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal Dexmedetomidine
Description: Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline
Study NCT01701778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexmedetomidine
Description: Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg
Study NCT01701778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline
Study NCT01701778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Induction and maintain anaesthesia
Study NCT01701778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sevoflurane
Description: Induction and maintain anaesthesia
Study NCT04189419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCM-AGH
Description: SCM-AGH will be administrated once a day for 3 days(D0, D1 and D2).
Study NCT04189419 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administrated once a day for 3 days(D0, D1 and D2).
Study NCT00839020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Navigated TKA with a minimally invasive approach
Description: Navigated total knee arthroplasty with a minimally invasive approach
Study NCT00839020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Navigated TKA with a conventional approach
Description: A navigated total knee arthroplasty is performed using the Orthopilot navigation system. A conventional approach is performed
Study NCT01234688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
Study NCT03906149 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia + standard medical care
Description: Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
Study NCT03906149 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
Study NCT03568825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopatic Manual Therapy (OMT)
Description: OMT consisting of following interventions; thoracic spine and diaphragm mobilisation, traction of the cardia and posture correction.
Study NCT03575182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait retraining program
Description: Supervised gait retraining with verbal and real-time visual feedback.
Study NCT03836729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide/emtricitabine
Description: TAF/FTC will be available as 25/200 milligrams (mg) tablet. Subjects will be administered TAF/FTC 25/200 mg QD via the oral route.
Study NCT03836729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
Study NCT02938910 — intervention group
Intervention type: OTHER
Intervention: non interventional study
Description: Non invasive imaging study without interventional procedures
Study NCT02020733 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Balloon catheter
Study NCT02020733 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: metal cannula
Study NCT05350683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: In the 12 hours prior to surgery, the principal investigator performed the remote ischemic preconditioning (RIPC) following the protocol: 4 cycles of inflation/deflation of a pneumatic arterial tourniquet on the non-dominant upper extremity. Considering inflated a pressure of 50mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of deflation. Patients included in the preconditioning group were randomized at a rate of 1:1 consecutively.
Study NCT01853007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COACH Program
Study NCT04510220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab (OMB157) is a fully human anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly subcutaneous injection that is in development for MS. Ofatumumab drug product (also referred as OMB157) is formulated as 20 mg/0.4 mL (50 mg/mL) solution for injection, provided in autoinjectors, for subcutaneous administration. The autoinjectors contain a small overfill to allow for a complete withdrawal of the labeled amount (20 mg) of ofatumumab.
Study NCT04510220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
Study NCT02310750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 oral solution/suspension
Description: Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
Study NCT02310750 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given during the single ascending and multiple dose periods
Study NCT02310750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 tablet
Description: PF-06700841 tablet formulation administered during the bioavailability / food effect investigation
Study NCT03671603 — intervention group
Intervention type: DRUG
Intervention: Iodixanol
Description: Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
Study NCT03719456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde Intrarenal Surgery
Study NCT03424681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil 300 mg by mouth daily
Study NCT03970304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivotif Typhoid Oral Vaccine
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Study NCT00519857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tibolone
Description: 1.25 mg p.o, once daily for 3 years
Study NCT00519857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet p.o, once daily for 3 years
Study NCT03424681 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04405700 — intervention group
Intervention type: OTHER
Intervention: Pharmacovigilance surveillance program
Description: The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).
Study NCT01600157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulant laparoscopic nephrectomy
Description: The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
Study NCT01873365 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Case report forms (CRFs), logbooks and booklets.
Study NCT00991354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX-B
Description: DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
Study NCT00991354 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 DNA plasmids
Description: Adjuvant for HIV vaccines
Study NCT04458948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 400 mg BID, on day 1 and then 200 mg BID day 2 through 7 IV or po for 5 days. If the condition of the patient does not allow for oral therapy, HCQ can be given via a feeding or NG tube. Azithromycin can be given intravenously.
Study NCT04458948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 500 mg, IV or po for 5 days
Study NCT04616157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT-I
Description: Cognitive-behavioral therapy for insomnia
Study NCT01934218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gel-One
Study NCT01934218 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PBS
Study NCT05520580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mother's push during CS
Description: after uterotomy, the mother was instructed and motivated to push for the delivery of the head and the shoulders of the baby. Simultaneously, the surgical assistant applied fundal pressure to support the mothers pushing if necessary
Study NCT00288158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Study NCT00288158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Study NCT00288158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT04214132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Counselling Application using Artificial Intelligence
Description: Intervention comprises of four Virtual Patients scenarios that aimed to improve nursing undergraduates communication skills in a clinical setting. These scenarios are based on authentic clinical cases (adapted from the real-life clinical case studies) focusing mainly on the communication aspects. Scenarios included 1) a middle-aged pregnant woman in her third trimester experiencing pain, 2) a middle-aged lorry driver who self-admitted to the hospital due to relapse of depressive symptoms, 3) changing a bloody dressing of a middle-aged male patient who had an operation 3 days ago, and 4) communicating with a fellow stressed student during their final preregistration clinical posting period.
Study NCT01333124 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy with Gemcitabine
Description: All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
Study NCT01333124 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: chemoradiotherapy with Gemcitabine
Description: Radiation: chemoradiotherapy with Gemcitabine
Study NCT03649828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic milk fermented with kefir grains
Description: Participants received probiotic milk fermented with kefir grains for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
Study NCT03649828 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curd
Description: Participants received the curd for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
Study NCT01573845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating + Eco-Friendly Campaign
Description: Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements
Study NCT01573845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Eating Campaign
Description: Participants receive a 6-month school-based campaign that includes:~* A 22-lesson classroom curriculum~* Homework activities that involve the family~* Monthly parent newsletters~* A food shopping and packing guide for parents~* Food demonstrations~* A poster contest~* School wide announcements
Study NCT03910257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education module
Description: 12 activities of nutrition education module will deliver by the teacher. The activities consists of coloring my meal plate, playing pictures, story telling: Zizi and Ziko, pictures station, fruits and vegetables card, cooking class, planting bean sprouts, field visit to fruits and vegetables garden, making collages, dot to dot, watching video, making healthy snacks
Study NCT01002157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (Vitamin K2)
Description: Menaquinone-7 (Vitamin K2)
Study NCT01002157 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Capsules containing no Menaquinone-7
Study NCT03263520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Description: Drug administration
Study NCT03263520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Drug administration
Study NCT03558997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab was administered SC in a single-use, pre-filled glass syringe
Study NCT02040480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 Gelatin Capsule
Description: White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration
Study NCT02040480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 IR Tablet
Description: White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
Study NCT03498248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenograstim
Description: injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy
Study NCT03558997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timothy Grass SCIT
Description: Timothy grass extract was administered SC.
Study NCT02837341 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Philips®Vital Sign Device - Camera-based system (Prototype)
Description: Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate
Study NCT03349450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
Study NCT03349450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
Study NCT03349450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
Study NCT01289912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast.
Study NCT01289912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast.
Study NCT02940990 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT concurrent with GM-CSF
Description: SBRT and GM-CSF 125ug/m2 for 14 days
Study NCT02940990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel
Description: two-drug regimen
Study NCT03558997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching dupilumab
Description: Placebo matching dupilumab was prepared in the same formulation without the addition of protein
Study NCT03558997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching SCIT
Description: Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract